Combination of MRI‐Guided High‐Intensity Focused Ultrasound and Bioluminescent Biological Systems to Assess Thermal Therapies for Tumor and Tumor Microenvironment
Source abstract
Abstract
Abstract This work presents an integrated technology for assessing in vivo anticancer treatments in mice, based on various heating conditions. Bioluminescence imaging (BLI) is used to assess the physiological response of tumor and tumor microenvironment (TME) to heat treatment induced by magnetic resonance‐guided high‐intensity focused ultrasound (MRgHIFU). Transgenic tumor cells and mouse models with either constitutive or thermo‐induced luciferase expressions are combined to monitor cell viability and heat‐induced processes in the tumor and TME. BLI performed after MRgHIFU heating shows that a moderate increase in temperature (45 °C) over 5 min can be exploited to promote heat‐activable treatments in the tumor and its TME, without inducing direct cell death. A higher temperature rise over a shorter exposure time can induce cell death in the tumor, as revealed by a reduction in the BLI signal after treatment. Under these conditions, BLI also reveals that the TME can be stimulated by heat without inducing necrosis. These integrated technologies and models are useful to assess, in vivo in mice, the efficacy of various anticancer strategies exploiting local heat deposition by noninvasive MRgHIFU, including those combining tumor ablation with local drug administration using thermosensitive nanovehicles.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ultrasound and Hyperthermia Applications · Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
IMOTION (Molecular Imaging and Innovative Therapies in Oncology) Bordeaux University, EA 7435 Bordeaux F‐33076 France
IHU LIRYC (Electrophysiology and Heart Modeling Institute) Hopital Xavier Arnozan Pessac F‐33600 France
Centre de recherche Cardio‐Thoracique de Bordeaux INSERM U1045 Bordeaux F‐33076 France
VIVOPTIC‐TBM Core Bordeaux University CNRS UMS 3427, INSERM US 005 Bordeaux F‐33076 France
References (66)
Show source-provided references
1. 10.1016/j.ccr.2012.02.02210.1016/j.ccr.2012.02.022 ↗
2. 10.3389/fonc.2020.58288410.3389/fonc.2020.582884 ↗
3. 10.1586/erd.12.7710.1586/erd.12.77 ↗
4. 10.1080/02656736.2016.121488410.1080/02656736.2016.1214884 ↗
5. 10.1080/02656736.2016.120969410.1080/02656736.2016.1209694 ↗
6. 10.3390/jfb802001910.3390/jfb8020019 ↗
7. 10.1007/s10103-013-1360-z10.1007/s10103-013-1360-z ↗
8. 10.1016/j.jsps.2016.04.00910.1016/j.jsps.2016.04.009 ↗
9. 10.1016/j.bulcan.2017.03.01010.1016/j.bulcan.2017.03.010 ↗
10. 10.1007/s00330-009-1532-110.1007/s00330-009-1532-1 ↗
11. 10.1002/mrm.2658810.1002/mrm.26588 ↗
12. Bour P. · Int. J. Hyperthermia · 2018 · 78 · 1911
13. 10.1021/nn404954s10.1021/nn404954s ↗
14. 10.1016/j.jconrel.2017.11.05010.1016/j.jconrel.2017.11.050 ↗
15. 10.1021/acsami.8b0239810.1021/acsami.8b02398 ↗
16. 10.1073/pnas.080693610610.1073/pnas.0806936106 ↗
17. 10.1002/mrm.2230910.1002/mrm.22309 ↗
18. 10.1007/s00330-011-2262-810.1007/s00330-011-2262-8 ↗
19. 10.1016/j.ultrasmedbio.2014.08.00810.1016/j.ultrasmedbio.2014.08.008 ↗
20. 10.1136/jnnp-2014-30764210.1136/jnnp-2014-307642 ↗
21. 10.1245/s10434-008-0011-210.1245/s10434-008-0011-2 ↗
22. 10.1007/s00330-018-5584-y10.1007/s00330-018-5584-y ↗
23. 10.1016/j.eururo.2015.12.02910.1016/j.eururo.2015.12.029 ↗
24. 10.2214/AJR.14.1309810.2214/AJR.14.13098 ↗
25. 10.1023/B:BREA.0000003956.11376.5b10.1023/B:BREA.0000003956.11376.5b ↗
26. 10.1007/s10549-004-5778-710.1007/s10549-004-5778-7 ↗
27. 10.1186/s40349-016-0055-x10.1186/s40349-016-0055-x ↗
28. 10.3390/nano807046810.3390/nano8070468 ↗
29. 10.1016/j.ctrv.2015.05.00910.1016/j.ctrv.2015.05.009 ↗
30. 10.3109/02656736.2012.68017310.3109/02656736.2012.680173 ↗
31. 10.1080/02656736.2018.155081510.1080/02656736.2018.1550815 ↗
32. 10.1021/acs.molpharmaceut.6b0001310.1021/acs.molpharmaceut.6b00013 ↗
33. 10.1080/02656736.2017.133667510.1080/02656736.2017.1336675 ↗
34. 10.1021/jacs.9b0759110.1021/jacs.9b07591 ↗
35. 10.1016/j.jconrel.2016.09.03010.1016/j.jconrel.2016.09.030 ↗
36. 10.1002/jgm.34510.1002/jgm.345 ↗
37. 10.1148/radiol.1010076710.1148/radiol.10100767 ↗
38. 10.1016/j.nano.2016.11.01410.1016/j.nano.2016.11.014 ↗
39. 10.18632/oncotarget.428810.18632/oncotarget.4288 ↗
40. 10.21037/atm.2016.01.3210.21037/atm.2016.01.32 ↗
41. 10.1155/2016/925137510.1155/2016/9251375 ↗
42. 10.1186/s40425-017-0284-810.1186/s40425-017-0284-8 ↗
43. 10.1038/s41598-020-80135-110.1038/s41598-020-80135-1 ↗
44. 10.1016/j.molonc.2008.04.00110.1016/j.molonc.2008.04.001 ↗
45. 10.1200/JCO.2007.14.306510.1200/JCO.2007.14.3065 ↗
46. 10.1371/journal.pone.021390510.1371/journal.pone.0213905 ↗
47. 10.1016/j.semcdb.2016.10.00110.1016/j.semcdb.2016.10.001 ↗
48. 10.3109/0265673090328621410.3109/02656730903286214 ↗
49. 10.1117/1.290466510.1117/1.2904665 ↗
50. 10.1109/RBME.2020.299512410.1109/RBME.2020.2995124 ↗
51. 10.3390/genes802006110.3390/genes8020061 ↗
52. 10.1364/BOE.5.00045710.1364/BOE.5.000457 ↗
53. 10.1038/nrc159110.1038/nrc1591 ↗
54. 10.1002/(SICI)1522-2594(200003)43:3<342::AID-MRM4>3.0.CO;2-610.1002/(SICI)1522-2594(200003)43:3<342::AID-MRM4>3.0.CO;2-6 ↗
55. 10.1118/1.315211210.1118/1.3152112 ↗
56. 10.1109/TBME.2009.203463610.1109/TBME.2009.2034636 ↗
57. 10.1038/s41598-018-22932-310.1038/s41598-018-22932-3 ↗
58. 10.1186/s40349-017-0104-010.1186/s40349-017-0104-0 ↗
59. 10.1007/s00259-012-2277-710.1007/s00259-012-2277-7 ↗
60. 10.1007/s11307-015-0864-210.1007/s11307-015-0864-2 ↗
61. 10.1002/j.1460-2075.1994.tb06337.x10.1002/j.1460-2075.1994.tb06337.x ↗
62. 10.1016/j.bbagen.2017.01.03610.1016/j.bbagen.2017.01.036 ↗
63. 10.4103/2228-7477.20559310.4103/2228-7477.205593 ↗
64. 10.1002/mrm.191034060610.1002/mrm.1910340606 ↗
65. 10.1002/mrm.191033011110.1002/mrm.1910330111 ↗
66. 10.1002/mrm.191040031610.1002/mrm.1910400316 ↗